Cardiovascular Effects in Psoriasis Patients Treated With Adalimumab.

NCT01320293 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]

Sponsor

University of North Carolina, Chapel Hill

Collaborators

[object Object]